News|Articles|October 4, 2023
Using Non-Infectious MVM and RVLP Surrogates to Predict Viral ClearanceInsourcing Purification Workflows Improves Efficiency, Recovery, and Quality
Author(s)Cygnus Technologies
Non-infectious mock virus particles that mimic the physicochemical properties of live infectious viruses can be used as spiking agents during viral clearance testing.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
FAQ: What You Need to Know About Agentic AI in Drug Discovery
2
Coya Raises $11.1 Million to Advance Immunomodulatory ALS Program
3
AstraZeneca’s $15 Billion Investment Deepens China R&D and Manufacturing Footprint
4
FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery
5